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Abstract
Background: Estimation of GFR (eGFR) using formulae based on serum creatinine concentrations are commonly used to
assess kidney function. Physical exercise can increase creatinine turnover and lean mass; therefore, this method may not
be suitable for use in exercising individuals. Cystatin-C based eGFR formulae may be a more accurate measure of kidney
function when examining the impact of exercise on kidney function. The aim of this study was to assess the agreement
of four creatinine and cystatin-C based estimates of GFR before and after a 12-month exercise intervention.
Methods: One hundred forty-two participants with stage 3–4 chronic kidney disease (CKD) (eGFR 25–60mL/min/1.73m2)
were included. Subjects were randomised to either a Control group (standard nephrological care [n = 68]) or a Lifestyle
Intervention group (12months of primarily aerobic based exercise training [n= 74]). Four eGFR formulae were compared
at baseline and after 12months: 1) MDRDcr, 2) CKD-EPIcr, 3) CKD-EPIcys and 4) CKD-EPIcr-cys.
Results: Control participants were aged 63.5[9.4] years, 60.3% were male, 42.2% had diabetes, and had an eGFR of 40.5 ±
8.9ml/min/1.73m2. Lifestyle Intervention participants were aged 60.5[14.2] years, 59.5% were male, 43.8% had diabetes,
and had an eGFR of 38.9 ± 8.5 ml/min/1.73m2. There were no significant baseline differences between the two groups.
Lean mass (r = 0.319, p < 0.01) and grip strength (r = 0.391, p< 0.001) were associated with serum creatinine at baseline.
However, there were no significant correlations between cystatin-C and the same measures. The Lifestyle Intervention
resulted in significant improvements in exercise capacity (+ 1.9 ± 1.8 METs, p< 0.001). There were no changes in lean
mass in both Control and Lifestyle Intervention groups during the 12months. CKD-EPIcys was considerably lower in both
groups at both baseline and 12months than CKD-EPIcr (Control =− 10.5 ± 9.1 and − 13.1 ± 11.8, and Lifestyle
Intervention = − 7.9 ± 8.6 and − 8.4 ± 12.3ml/min/1.73m2), CKD-EPIcr-cys (Control = − 3.6 ± 3.7 and− 4.5 ± 4.5, and
Lifestyle Intervention =− 3.6 ± 3.7 and − 2.5 ± 5.5ml/min/1.73m2) and MDRDcr (Control = − 9.3 ± 8.4 and− 12.0 ± 10.7,
Lifestyle Intervention =− 6.4 ± 8.4 and − 6.9 ± 11.2ml/min/1.73m2).
Conclusions: In CKD patients participating in a primarily aerobic based exercise training, without improvements in lean
mass, cystatin-C and creatinine based eGFR provided similar estimates of kidney function at both baseline and after 12
months of exercise training.
Trial registration: The trial was registered at www.anzctr.org.au (Registration Number ANZCTR12608000337370) on the
17/07/2008 (retrospectively registered).
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Background
The most common approach used to assess kidney func-
tion is by estimation of glomerular filtration rate (eGFR)
based on serum creatinine concentrations, as it can be
calculated routinely from standard tests and is inexpen-
sive. Physical exercise can cause an increase in serum
creatinine; [1] therefore this method may not be suitable
for use in exercising individuals. Alternatively, cystatin-C
based eGFR is suggested to be an improved method for
eGFR measurement and may provide a more precise
measure of kidney function [2]. The agreement between
cystatin-C and creatinine based eGFR before and after
an exercise intervention in chronic kidney disease
(CKD) patients is yet to be studied.
The current reference method for measuring kidney
function is to quantify the clearance of an exogenous
marker, such as inulin, to determine GFR [3]. However,
this measure is rarely used clinically due to the test com-
plexity and cost. Instead, indirect assessment of endogen-
ous markers to provide an estimation of GFR is
commonly used for routine clinical measurements via dif-
ferent formulas [4]. These formulae use either a measure
of creatinine or cystatin-C in serum or urine, along with
patient characteristics; age, sex and race to estimate filtra-
tion rates. The four most frequently used eGFR equations
are: 1) modification of diet in renal disease-creatinine
(MDRDcr) [5], 2) chronic kidney disease-epidemiology
collaboration (CKD-EPI)cr [6], CKD-EPIcystatin-C(cys)
[7] and CKD-EPIcr-cys [7].
Creatinine based eGFR measures are commonly used as
a ‘first test’ and for routine clinical assessment of kidney
function [7, 8]. Creatine phosphate is taken up by muscle
after it is released into the circulatory system following
synthesis in the liver. Creatinine is formed as the
by-product of muscle creatine breakdown during muscle
contraction [9] and therefore can be directly influenced by
muscle mass [10, 11]. This is an important limitation for
estimation of GFR in a population such as CKD who typ-
ically have reduced muscle mass [11]. Furthermore, in-
tense exercise may cause a breakdown of muscle leading
to an increase in serum creatinine levels, [1] potentially
making creatinine-based eGFR measures inaccurate in ex-
ercising individuals. Cystatin-C is a low molecular weight
cystine protease inhibitor that is produced at a constant
rate by all nucleated cells and is not influenced by muscle
mass [12]. The use of cystatin-C to calculate eGFR is sug-
gested by some as an alternative measure of eGFR due to
its increased association with risk of death and progres-
sion to end-stage renal disease [13].
Exercise training is important for patients with CKD
as it has been shown to improve physical function and
cardiovascular risk factors in a number of studies [14–
16]. Therefore, it is important to identify whether there
is a difference in the agreement between cystatin-C and
creatinine based eGFR measures after exercise-induced
adaptations occur. It is also important to assess the im-
pact of exercise training on kidney function – such as by
slowing the rate of decline or the potential for harm by
volume depletion.
The aim of this study was to assess the agreement be-
tween cystatin-C and creatinine based eGFR estimates
following a primarily aerobic exercise intervention. It
was hypothesised that there would be poor agreement
between these measures after 12 months of exercise
training due to the impact of exercise on muscle break-
down and thereby serum creatinine.
Methods
The data from this study is a 12-month analysis from the
‘LANDMARK III’ study (Longitudinal Assessment of Nu-
merous Discrete Modifications of Atherosclerotic Risk Kid-
ney disease), a randomised control trial looking at the effects
of a 3-year multi-disciplinary lifestyle intervention in pa-
tients with CKD. This study included 142 subjects with
stage 3–4 CKD (MDRDcr-175 eGFR 25–60mL/min/1.73m
2)
(Fig. 1). Inclusion criteria: aged 18 to 75 years and at least
one of the following risk factors – blood pressure or lipids
not at target; overweight (body mass index [BMI] > 25 kg/
m2); and poor diabetic control (haemoglobin A1c > 7%). Ex-
clusion criteria were: intervention for, or, symptomatic cor-
onary artery disease (within 3months), current heart failure
(New York Heart Association class III and IV) or significant
valvular heart disease, pregnant or planning to become preg-
nant and life expectancy or anticipated time to dialysis or
organ transplant < 6months. Participants were asked to re-
frain from any exercise on the morning of the test.
Exercise program
Intervention participants were treated by a multidisciplin-
ary team consisting of Exercise Physiologists, Nurse Practi-
tioners, Dieticians, Diabetic Educator and Nephrologists.
Participants trained for 8 weeks, a minimum of twice per
week with an Exercise Physiologist in a supervised
gym-based setting. The gym-based training incorporated a
combination of aerobic and resistance exercises. After the
8 weeks of gym-based training, patients completed a home
program for 10months with regular gym refresher sessions,
and regular follow-up via telephone and email. The home
program consisted of resistance exercises based on a pro-
vided thera-band and swiss ball, with a large emphasis on
aerobic training. A more detailed description of the lifestyle
intervention is outlined in Howden et al. (2013) [17].
Creatinine and cystatin-C measurements
Serum vacutainers (BD vacutainers, NJ, USA) were used to
collect 10mL venous blood samples following an overnight
fast. Creatinine was measured by the Jaffe method on a
Beckman DxC800 general chemistry analyser (Beckman
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Coulter Diagnostics, Brea, CA, USA). A particle-enhanced
immunoturbidimetric assay (Cystatin-C Tina-quant Roche/
Hitachi- Roche Diagnostics GmbH. Mannheim Germany)
on a COBAS Mira clinical autoanalyser (Roche Diagnostica
Switzerland), was used to perform serum cystatin-C mea-
surements according to the manufacturer’s instructions.
Control and calibration materials were provided by Roche
Diagnostics. A 2-reagent assay system was used, in where
reagent 1 is a buffer and reagent 2 is a suspension of latex
particles coated with rabbit anti-cystatin-C specific poly-
clonal antibodies. The sample is mixed with reagent 1 in a
cuvette and incubated for 3min, after which reagent 2 is
added. After 7.5min from the start of the cohesion reac-
tion, of wavelength 550 nm, the absorbance difference was
measured. All cystatin-C measures were performed in du-
plicate and the average was taken. If there was a difference
of greater than 10% between 2 measures, a 3rd measure
was taken and if the 3 values were similar, the average was
taken, or if an outlier of the 3 was detected it was deleted.
Our intra-assay coefficient of variation based on duplicate
measures was 3.8%.
eGFR measurements
Four measures of renal function were assessed by eGFR;
MDRDcr– 175 study eq. (2006), [18] CKD-EPIcr eq.
(2009), [6] CKD-EPIcys eq. (2012) [7] and CKD-EPIcr-cys
eq. (2012) [7]. Table 1 outlines the calculations used for
each formula. All eGFR’s are made relative to a surface
area of mL/min/1.73m2.
Fitness measures
A hand grip dynamometer was used to assess grip
strength (Jamar 5030 J1, Illinois, United States). The
maximum grip strength was recorded from the highest
of three readings of either hand. An improvement in
grip strength was determined by an increase from base-
line to 12 months. Peak oxygen uptake (VO2peak) mea-
sured by expired air analysis was used to assess
cardiorespiratory fitness (Vmax29c, SensorMedics, CA,
USA), using the peak 20 s average of the final minute
during a maximal treadmill test. The test protocol used
was either Bruce, Balke or Naughton protocols, based
on participants responses to the Duke Activity Status
Index, and the same test was performed pre and post
intervention [19]. Exercise capacity was determined from
the treadmill test as estimated metabolic equivalent tasks
(METs) (GE Case V6.51, Wisconsin, USA) and from a
six-minute walk test. Muscular power was measured
using the Get up and Go test, from a 3-m timed lap
from a non-armed chair. The best time in seconds from
three successive trials was used as the final time.
Physical activity
The self- reported Active Australia (AA) questionnaire
was used to assess average weekly physical activity levels
from the preceding six months. [20] Questions from the
AA used in the data analysis are; average weekly time, in
the past six months, for time spent walking (for at least
10 min without stopping), time spent doing moderate in-
tensity activity and time spent doing vigorous activity.
The questions were asked by an Accredited Exercise
Physiologist to avoid any misunderstanding by the sub-
ject and clarity was checked on each question. Partici-
pants were required to provide examples of the activity
that they reported in each of the three categories (walk-
ing, moderate and/or vigorous) in order to limit
over-representation of an activity. Standardized exam-
ples for each category (eg. moderate = gentle swimming/
Fig. 1 Consort diagram
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social tennis/golf; vigorous = jogging/cycling/aerobics/
competitive tennis) were provided to the participant as
suggested on the AA questionnaire.
The metabolic equivalent of a task provides an esti-
mate of energy cost to a physical activity [21]. There-
fore, an activity of higher intensity would have a
higher MET score. According to the International
Physical Activity Questionnaire, MET intensities were
calculated by time in each intensity multiplied by ei-
ther 8 (vigorous), 4 (moderate) and 3.3 (walking), re-
spectively (www.ipaq.ki.se). Total MET hours are
calculated by the addition of vigorous MET hours,
moderate MET hours and walking MET hours. An
improvement in total MET hours is determined by an
increase from baseline to 12 months.
Lean mass
Dual energy x-ray absorptiometry (DEXA), using
whole body composition analysis was used to assess
lean mass (Hologic QDR 4500A Version 12.6, Massa-
chusetts, USA). To assess skeletal muscle separate to
lean tissue, [22] trunk lean mass was removed from
the lean mass total. As such, lean mass was estimated
from analysis from the appendicular skeleton and the
average of the four limbs was calculated. DEXA was
performed on a representative sub-set of patients due
to limited machine availability (n = 73). The DEXA
was performed prior to the exercise stress test on the
day of testing.
Statistics
Mean ± standard deviation (SD) was used to describe
normally distributed baseline characteristics, with per-
centages used to describe frequencies for categorical
variables. Median [IQR] was used to describe not nor-
mally distributed variables and variables transformed
by the natural logarithm. Pearson’s correlation was
used to assess association for normally distributed
and log transformed variables. Comparison between
groups was assessed by an independent t-test of the
delta from baseline to 12 months. Mann-Whitney U
test was performed on not-normally distributed vari-
ables. Differences between groups for categorical vari-
ables were analysed using Pearson’s Chi Square test.
Within group differences were assessed by paired
t-tests for normally distributed and log transformed
variables. Wilcoxon-Sign rank test was used for not
normally distributed variables. A multiple linear re-
gression was used to identify independent correlates
with change in eGFR measures, using the enter
method. Bland-Altman analysis was used to assess
agreement between eGFR measurements using Graph-
Pad Prism 7. All other statistical analyses were per-
formed on IBM SPSS Statistics 22. With many
repeated variables in a large sample size, a small
amount of missing data for variables were inevitable.
Participants were included in the analysis (ie. n = 142)
if they had either cystatin-C or creatinine measures
(and therefore their subsequent eGFR measures) at
both baseline and 12 months. Statistical significance
was set at p < 0.05.
Results
Patient characteristics
There were no significant differences between groups
for any of the baseline characteristics or medication
use (Table 2). Patients were on average 62 years of
age and generally obese with an average BMI of 32
kg/m2. Mean VO2peak for the group was considered
very poor, according to the American College of
Sports Medicine (2010) normative values for men
and women aged 60–69, at 23.6 ml/kg/min [23]. The
number of participants who changed their hyperten-
sive or diuretic medication (commenced, ceased or
no change) was not significantly different between
the control and LI groups (Table 3).
Table 1 eGFR equations
Name Sex Cr Cys Equation
MDRD (2006) [18] 175xcr-1.154xage-0.203(× 0.742,if female)(× 1.212,if black)
CKD-EPIcr (2009) [6] F ≤0.7 144x(cr/0.7)-0.329 × 0.993age(× 1.159,if black)
>0.7 144x(cr/0.7)-1.209 × 0.993age(× 1.159,if black)
M ≤0.9 141x(cr/0.9)-0.411 × 0.993age(×1.159,if black)
>0.9 141x(cr/0.9)-1.209 × 0.993age(×1.159,if black)
CKD-EPIcys (2012) [7] F ≤0.8 133x(cys/0.8)-0.499 × 0.996agex0.932
>0.8 133x(cys/0.8)-1.328 × 0.996agex0.932
M ≤0.8 133x(cys/0.8)-0.499 × 0.996age
>0.8 133x(cys/0.8)-1.328 × 0.996age
CKD-EPIcr-cys (2012) [7] 130x(cr/0.7)-0.248x(cys/0.8)-0.375 × 0.995age(×1.08,if black)
MDRD modification of diet in renal disease, CKD-EPI chronic kidney disease epidemiology collaboration, cr creatinine, cys cystatin-C, F female, M male
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Association between creatinine and lean mass and
strength
Table 4 shows correlations between kidney function esti-
mates with fitness and body composition measures in all
patients at baseline. Creatinine was significantly associated
with lean mass (r = 0.32, p < 0.01) and grip strength (r =
0.39, p < 0.001). Cystatin-C however was not correlated
with lean mass or grip strength.
Fitness measures
An additional file demonstrates the baseline and
within group changes in all patient characteristics in
Table 2 Baseline characteristics
Variable Control (n = 68) LI (n = 74) p value
Age (years) 63.5[9.4] 60.5[14.2] 0.23
Male sex, n(%) 41(60.3) 44(59.5) 0.92
African, n(%) 0(0) 1(1.4) 0.34
Diabetes, n(%) 27(42.2) 32(43.8) 0.85
Systolic blood pressure (mmHg) 133[26.5] 130[18] 0.18
Diastolic blood pressure (mmHg) 80[12] 78[10] 0.56
Medications
ACE inhibitor, n(%) 34(53.1) 34(47.9) 0.54
ARB, n(%) 30(45.5) 44(59.5) 0.10
Thiazide, n(%) 16(25) 13(18.3) 0.35
Spironolactone, n(%) 1(1.4) 3(4.9) 0.89
Loop diuretics, n(%) 14(20.6) 15(21.2) 0.24
Statin, n(%) 41(64.1) 46(64.8) 0.93
Primary cause of renal disease
Glomerular nephritis, n(%) 2(2.9) 7(9.5) 0.11
Analgesic nephropathy, n(%) 0(0) 2(2.7)
Renal vascular disease, n(%) 5(7.4) 5(6.8) 0.89
Polycystic kidney disease, n(%) 4(5.9) 4(5.4) 0.90
Reflux nephropathy, n(%) 1(1.5) 1(1.4) 0.95
Pyelonenephritis, n(%) 1(1.5) 1(1.4) 0.95
Calculi, n(%) 0(0) 1(1.4)
Type 1 diabetes (insulin), n(%) 0(0) 1(1.4)
Type 2 diabetes (non-insulin), n(%) 3(4.4) 5(6.8) 0.55
Type 2 diabetes (insulin), n(%) 10(14.7) 5(6.8) 0.12
Focal segmental glomerulosclerosis, n(%) 3(4.4) 2(2.7) 0.58
IgA nephropathy, n(%) 4(5.9) 4(5.4) 0.90
Other, n(%) 24(35.3) 21(28.4) 0.38
Unknown, n(%) 5(7.4) 6(8.1) 0.87
ACE angiotensin-converting-enzyme, ARB angiotensin receptor blocker. Median[IQR] and n(%) is reported
Table 3 Change in hypertensive and diuretic medications during the 12-month study period
Medication Control LI P value
Commenced Ceased Commenced Ceased
ACE inhibitor, n(%) + 1(1.5) −5(7.4) + 1(1.4) −7(9.5) 0.83
ATRB, n(%) + 4(5.9) − 2(2.9) +6(8.1) − 6(8.1) 0.30
Thiazide, n(%) + 1(1.5) −2(2.9) + 1(1.4) −3(4.1) 0.90
Spironolactone, n(%) 0 −2(2.9) 0 0
Loop diuretics, n(%) +6(8.8) −3(4.4) + 4(5.4) −3(4.1) 0.76
ACE angiotensin-converting-enzyme, ATRB angiotensin receptor blocker
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the LI and Control groups (see Additional file 1).
Compared to the Control group, the LI group had
significant (p < 0.05) improvements in VO2peak and
METs and a close to significant (p = 0.05) increase in
6-min walk time. There were also significant treat-
ment effects with get up and go time, moderate in-
tensity activity, time spent walking and total activity,
such that the intervention group demonstrated in-
creases in these variables. There were no significant
(p > 0.05) between-group differences in appendicular
lean mass, grip strength or vigorous intensity exer-
cise. There were also no within group changes in
lean mass or vigorous intensity exercise in the LI
group.
Kidney function
The additional file shows no significant within group
changes in the LI group for any of the kidney function mea-
sures (see Additional file 1). The Control group had a sig-
nificant increase in cystatin-C over 12months with
subsequent decreases in CKD-EPIcys and CKD-EPIcr-cys.
There were no significant between group differences for
any of the changes in eGFR measures over the 12months.
A multiple linear regression also identified no association
between change in each of the eGFR measures, and change
in appendicular lean mass, maximal grip strength or phys-
ical activity (Table 5).
Agreement of eGFR measures
Tables 6 and 7 shows the agreement between CKD-EPIcys
with the other three estimates at baseline in both LI and
Control groups. The Bland-Altman analysis identified
CKD-EPIcys and CKD-EPIcr-cys to be considerably lower
than CKD-EPIcr and MDRDcr for estimating GFR. Fig-
ures 2 and 3 indicates CKD-EPIcys records lower average
values than CKD-EPIcr at baseline in both LI (eGFR 7.9
below CKD-EPIcr) and Control groups (eGFR 10.5 below
CKD-EPIcr). This difference was consistent at 12months in
both LI (eGFR 8.4 below CKD-EPIcr) (Table 8) and Control
groups (eGFR 13.1 below CKD-EPIcr) (Table 9). Only
CKD-EPIcys and CKD-EPIcr are reported in Figs. 2, 3, 4
and 5, to demonstrate the difference between cystatin-C
and creatinine using similar equations (CKD-EPI).
Discussion
This is the first study to investigate the agreement be-
tween cystatin-C and creatinine based eGFR measures be-
fore and after a 12-month exercise intervention. The
findings from this study indicate that 1) cystatin-C based
Table 4 Associations between kidney function estimates with fitness and body composition in all patients at baseline
Baseline (r value)
Creatinine Cystatin-C EPIcr EPIcys EPIcr-cys MDRD
VO2peak 0.11 −0.04 0.20* 0.16 0.20* 0.18*
VO2peak/lean − 0.15 − 0.10 0.17 0.12 0.15 0.12
Appendicular lean mass 0.32** 0.12 −0.06 0.004 −0.01 − 0.05
Grip strength 0.39** 0.02 0.01 0.11 0.08 0.02
** = p <0.01, * = p <0.05
Table 5 Change in appendicular lean mass, total physical activity
time and grip strength on change in eGFR, independent of
baseline eGFR using multiple linear regression
β P value
Delta MDRD (r2 = 0.206, p = 0.24)
Delta Appendicular lean mass −0.15 0.45
Delta maximal grip strength −0.39 0.06
Delta total physical activity time 0.07 0.75
Baseline MDRD 0.220 0.28
Delta CKD-EPIcr (r2 = 0.181, p = 0.31)
Delta Appendicular lean mass −0.17 0.40
Delta maximal grip strength −0.37 0.07
Delta total physical activity time 0.07 0.73
Baseline CKD-EPIcr 0.12 0.55
Delta CKD-EPIcys (r2 = 0.293, p = 0.12)
Delta Appendicular lean mass 0.07 0.73
Delta maximal grip strength 0.03 0.90
Delta total physical activity time 0.28 0.16
Baseline CKD-EPIcys −0.43 0.04
Delta CKD-EPIcr-cys (r2 = 0.157, p = 0.47)
Delta Appendicular lean mass −0.10 0.62
Delta maximal grip strength −0.25 0.26
Delta total physical activity time 0.17 0.45
Baseline CKD-EPIcr-cys −0.20 0.35
Table 6 Bland-Altman agreement of eGFR at baseline in LI
patients
EPIcr EPIcr-cys MDRDcr
EPIcys −7.9 ± 8.6 −3.6 ± 3.7 −6.4 ± 8.4
EPIcr 5.3 ± 5.0 1.5 ± 3.0
EPIcr-cys − 4.0 ± 5.0
Data is reported as the difference ± SD of the difference
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eGFR estimates were considerably lower than creatinine
eGFR estimates; 2) lean mass and grip strength were cor-
related with creatinine and not cystatin-C at baseline; and
3) the agreement between cystatin-C and creatinine eGFR
was consistent at baseline and after the LI.
The Bland-Altman analysis showed a considerably lower
eGFR measured by CKD-EPIcys than by CKD-EPIcr and
MDRDcr. Not surprisingly, the agreement between
CKD-EPIcr and MDRDcr was also significant. Furthermore,
as expected, the difference between CKD-EPIcr-cys was mid-
way between CKD-EPIcr and MDRDcr, and CKD-EPIcys.
An overestimation of eGFR using the MDRDcr equation has
previously been reported by Lamb, et al. [24]. CKD-EPIcr is
thought to produce less biased estimates of GFR at higher
levels of kidney function, however is less accurate when GFR
falls below 60ml/min/1.73m2 [25]. On the other hand,
cystatin-C is suggested to be a more sensitive marker of GFR
than creatinine [26]. This is supported in our study, evident
by the lower CKD-EPIcys and CKD-EPIcr-cys identified by
the Bland-Altman plots when compared to CKD-EPIcr and
MDRDcr. The lower lean mass and strength in the study
population [27] may be contributing to the higher
CKD-EPIcr and MDRDcr measures compared to cystatin-C.
Despite the lower CKD-EPIcys at baseline, it is important to
note the agreement between the cystatin-C and creatinine
based eGFR measures do not significantly differ after 12
months of exercise training. Due to the routine measure-
ment of CKD-EPIcr and MDRDcr in standard clinical care,
these findings support the use of creatinine based eGFR
measures in exercising individuals.
The findings from this study identified that lean mass
and grip strength were correlated with creatinine and not
cystatin-C at baseline. This finding is in agreement with
evidence that lean mass is significantly related to serum
and urinary creatinine but not with cystatin-C, even after
adjustment for physical activity levels [11]. From the base-
line findings of creatinine correlating with lean mass and
grip strength, it would appear that muscle mass and
strength would be influencing creatinine based eGFR esti-
mates (CKD-EPIcr and MDRDcr). Although the small
sample size limits the ability to detect a significant change
in eGFR, the findings indicate that an exercise interven-
tion such as the one reported in this study, does not influ-
ence creatinine based eGFR measures.
The equations used to estimate GFR have advanced in
precision and accuracy. In 1999 the MDRDcr equation
was suggested to be more accurate than the accepted
Cockcroft-Gault and creatinine clearance methods [28].
More recently it was proposed that CKD-EPIcr provided a
more precise estimate of GFR and categorisation for risk
of mortality compared to the MDRDcr study equation
[29]. CKD-EPIcr was developed using the same variables
as MDRDcr but with different coefficients, which created
a moderate improvement in overall accuracy [30]. It has
been suggested that standardised serum creatinine assays
be used as a first test for assessing eGFR in adults due to
its cost-effectiveness, and that Cystatin-C be used as a
more precise confirmatory test if a below normal creatin-
ine eGFR is detected [8].
Table 7 Bland-Altman agreement of eGFR at baseline in Control
patients
EPIcr EPIcr-cys MDRDcr
EPIcys −10.5 ± 9.1 −3.6 ± 3.7 −9.3 ± 8.4
EPIcr 6.9 ± 5.5 1.4 ± 1.9
EPIcr-cys −4.0 ± 5.0
Data is reported as the difference ± SD of the difference
Fig. 2 Bland-Altman plots at baseline in LI patients for CKD-EPIcr compared to CKD-EPIcys. CKD-EPIcys minus CKD-EPIcr is divided by the mean of
CKD-EPIcys+CKD-EPIcr. CKD-EPIcys is shown to be 7.9 ± 8.6 mL/min/1.73m2 less than CKD-EPIcr at baseline
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Banfi, et al. [31] identified elevated serum creatin-
ine concentration levels in athletes compared to sed-
entary controls, proposed to be attributable to
higher muscle mass. It is also suggested that the ob-
served eGFR reductions are limited to periods when
the athlete is unaccustomed to the training load.
This is not unlike a CKD patient commencing an
exercise program after an extended sedentary period.
However, it is promising to note there was no reduc-
tion in eGFR in the intervention group of the
current study, despite a large increase in physical ac-
tivity levels. This is supported by a number of stud-
ies who have shown maintenance of kidney function
with exercise training [16, 32]. An intervention
resulting in significant increases in strength and
mass, such as with a specific hypertrophy resistance
training program, may potentially provoke a decline
in eGFR using creatinine based equations. Indeed,
the lack of change in lean mass in the current study
limits the ability to make conclusions regarding the
effects of exercise induced gains in lean mass on
eGFR measures. As such, clinical decisions based on
creatinine based eGFR’s of patients undertaking
hypertrophy training should be considered with
caution. Although the small sample size limits the
ability to detect a significant change in eGFR, [25]
the findings from this study suggest that primarily
aerobic based exercise training with limited resist-
ance exercise, is not enough to elicit changes in
eGFR. Future studies should investigate whether spe-
cific hypertrophy interventions influence creatinine
based eGFR measures. It was not expected that there
would be no changes in grip strength and lean mass
in the current study. However, in this generalizable
CKD cohort the lack of increase in grip strength and
lean mass is an important finding and warrants fur-
ther investigation.
Cystatin-C also has some reported limitations in
its use as a kidney function measure, due to its asso-
ciations with cardiovascular risk factors. After mod-
elling to adjust for measured GFR, Rule, et al. [33]
found residual associations of CKD-EPIcys with CKD
risk factors, including hypertension, BMI, and
c-reactive protein (CRP). This confounding associ-
ation makes it difficult to establish whether
cystatin-C is a true measure of renal function or ra-
ther a reflection of cardiovascular disease risk factors
[12]. Due to the limitations of both endogenous
Fig. 3 Bland-Altman plots at baseline in the control group for CKD-EPIcr compared to CKD-EPIcys. CKD-EPIcys minus CKD-EPIcr is divided by the
mean of CKD-EPIcys+CKD-EPIcr. CKD-EPIcys is shown to be 10.5 ± 9.1 mL/min/1.73m2 less than CKD-EPIcr at baseline
Table 8 Bland-Altman agreement of eGFR at 12 months in LI
patients
EPIcr EPIcr-cys MDRDcr
EPIcys −8.4 ± 12.3 −2.5 ± 5.5 −6.9 ± 11.2
EPIcr 5.9 ± 6.9 2.2 ± 5.0
EPIcr-cys −4.3 ± 6.2
Data is reported as the difference ± SD of the difference
Table 9 Bland-Altman agreement of eGFR at 12 months in
Control patients
EPIcr EPIcr-cys MDRDcr
EPIcys −13.1 ± 11.8 − 4.5 ± 4.5 −12.0 ± 10.7
EPIcr 8.6 ± 7.4 1.1 ± 2.2
EPIcr-cys −7.5 ± 6.4
Data is reported as the difference ± SD of the difference
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kidney function measures, it has been suggested that
using the combination of creatinine and cystatin-C
used in the CKD-EPI equation provides the most ac-
curate assessment of kidney function [8, 33, 34].
This study had some limitations. Physical activity under-
taken in the 24-h period preceding testing was not re-
corded. If the exercise was of high enough intensity it may
potentially have resulted in transient increases in serum
creatinine. Nevertheless, in the current study testing was
completed in the morning after an overnight fast, and par-
ticipants were asked to refrain from any strenuous exercise
the morning of the test. Patients who begin taking, or have
an increase in dose of angiotensin converting enzyme
inhibitor, angiotensin receptor blocker, famotidine,
ranitidine and antibiotics trimethoprim-sulfamethoxazol,
H2-blocker cimetidine and cefoxitin may have an increase
in serum creatinine [35]. As the dose of medications was
not recorded, the impact of these on any potential changes
in eGFR creatinine equations is unknown and is therefore a
limitation of the study.
A significant limitation which needs to be addressed
is the large sample size needed to see a change in
Fig. 4 Bland-Altman plots at 12 months in LI patients for CKD-EPIcr compared to CKD-EPIcys. CKD-EPIcys minus CKD-EPIcr is divided by the mean
of CKD-EPIcys+CKD-EPIcr. CKD-EPIcys is shown to be 8.4 ± 12.3 mL/min/1.73m2 less than CKD-EPIcr
Fig. 5 Bland-Altman plots at 12 months in the control group for CKD-EPIcr compared to CKD-EPIcys. CKD-EPIcys minus CKD-EPIcr is divided by
the mean of CKD-EPIcys+CKD-EPIcr. CKD-EPIcys is shown to be 13.1 ± 11.8 mL/min/1.73m2 less than CKD-EPIcr
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eGFR. As suggested by Lamb, et al. [25], 1000 partici-
pants are needed to detect differences in accuracy of
measurement between MDRDcr and CKD-EPIcys.
The authors of this pilot study found in 1000 sub-
jects, the simulations showed an 87% power at the
5% significance level to detect a difference of 5%. The
current study did not have the resources to provide
longitudinal exercise training on this scale. It is for
this reason that the focus of this study was on the
agreement between the measures, rather than asses-
sing statistical changes. Future large-scale exercise in-
terventions comparing creatinine and cystatin-C
estimates of GFR measures are needed to explicitly
address the hypothesis from this study.
Conclusions
The findings from this study found no difference in the
agreement between creatinine and cystatin-C estimates of
GFR after a 12-month LI. If only creatinine-based mea-
sures are accessible to the treating Physician, the findings
from this study suggest it is reasonable to expect creatin-
ine based measures to be a sufficient measure after pre-
scription of a health-enhancing exercise program. Future
exercise training studies comparing cystatin-C and cre-
atinine based eGFR measures in specific hypertrophy and
high intensity training programs are warranted to confirm
the current findings.
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